Poseida Therapeutics and Rapha Capital Management Rapha Capital Management Participates in Series D Financing for Poseida Therapeutics June 25, 2020
Read More
Asclepix Therapeutics, Inc. Better than Eylea, as durable as gene therapy? Perceptive, Xontogeny boost ophthalmic startup’s shot for best of all worlds Amber Tong, Editor, ENDPOINTS NEWS June 24, 2020
Asclepix Therapeutics, Inc. AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis Frank Vinluan, Editor, Xconomy June 24, 2020
Asclepix Therapeutics, Inc. AsclepiX Therapeutics Announces $35 Million Series A Financing Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing…